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ABSTRACT
Background: Review of recent journal articles and various relevant current textbooks provides strong evidence
to show that anticholinergic burden is a material issue in frail and at-risk patients. This study assesses
the anticholinergic burden in a group of patients in residential care facilities and then applies a theoretical
intervention model. It is based on a scoring system known as the Anticholinergic Cognitive Burden (ACB)
scale, and attempts to reduce the anticholinergic burden while maintaining therapeutic benefits.
Methods: A database of 691 patients was analyzed for each individual’s ACB based on the scale of scoring
produced by groups of experts in the area. A theoretical intervention was then conducted using relevant,
evidence-based practice guidelines for clinical therapeutics in Australia. The intervention had the aim of
reducing the total ACB without affecting the apparent intended effectiveness of the prescribed therapy.
Results: Of the 35% (n = 242) patients who score at least 1 point on the ACB, a reduction is achievable in
59% of the cases. In particular, the reduction from a clinically significant score of 3 or above to 2 or below for
49 of those patients is possible in 85% of the cases. Overall, this represents a reduction from 7.10% to 1.01%
for the entire population. It is also found that of the 246,960 counts of items dispensed (both prescription and
non-prescription) for these patients, 47,334 (or 19.2%) of these were of agents on the ACB scale.
Conclusions: The study found that it appears to be possible that the total ACB of a group of 691 patients can
be significantly reduced.
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Introduction
Nearing the end of the second decade of life, the
human body would have reached its full potential
development, up to and including cognitive func-
tions and maturation of the central nervous system
(CNS). It is from this point that it reaches the stage
of inevitable decline, which continues until death
(Hutchison and O’Brien, 2007). This aging pro-
cess is often accompanied by diminishing bodily
and overall physiological reserve. It is worth not-
ing that the trend and rate of functional reserve
decline differs greatly between individuals, hence
there are always variations in any sample population
(Rockwood et al., 2011).
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Frailty – what does it mean to be “frail”?
Frailty is not an easy concept to define. Most ex-
perienced clinicians can and do correctly identify
“frail” patients who come into their care, although
this would be considered mostly instinctive. The
challenge then lies in finding the definitions for, and
quantifying the level of frailty.
The problems arise when researchers look for
factors to include or exclude in an appropriate
sample group (Rockwood, 2005; Rockwood and
Mitnitski, 2007). Traditionally, the focus of frailty
lies in the measure of patients’ abilities in cognition,
continence, mobility, and function. These are relat-
ively simple parameters to measure and give reason-
able predictive validity (Davis et al., 2011). It should
be emphasized that, although there is a positive cor-
relation between advancing age and frailty, they are
not dependent variables of each other (Rockwood
and Mitnitski, 2011). Patients who are frail are
particularly predisposed to the unwanted effects of
systemic anticholinergic agents. This may in-
clude delirium, xerostomia, visual disturbance, and
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iatrogenic impairment of cognitive function, such as
short-term memory.
Some patients of advancing age may require as-
sistance to the extent that they need multiple daily
dosing of their medications put into clearly labeled
slots on disposable devices. Such devices, labeled
as “Days of the Week” and time slots (e.g. break-
fast, lunch, and dinner time), allow patients or their
carers or nursing staff in aged care facilities to ad-
minister the medication and keep track of compli-
ance. Such systems may be known as “dosing ad-
ministration aids” (DAA).
Anticholinergics – Why are they targeted?
It is established that a frail individual (at least from
pharmacokinetics perspective) should be treated
differently from their non-frail counterparts (Agar
et al., 2009). This is especially the case with med-
ications possessing anticholinergic effects. In this
section, sample medications will be used to demon-
strate how anticholinergics affect the frail in a man-
ner that differs from the effects on “normal 25-year-
old Caucasian male” (Abe et al., 2009), in which so
many phase-1 trials of medications are performed.
Some of these medications may be used for their
anticholinergic properties for the desired action, but
these are also often associated with side effect pro-
files (Nishtala et al., 2009).
Which medications are most frequently
implicated?
Authors in this field tend to assign an artificial value
as a means of quantifying the predicted anticholin-
ergic impact of these medications (Carnahan et al.,
2006). The numbers are usually between 0 and 3,
with zero being “no anticholinergic activities,” and
3 being the highest single contributor to the antich-
olinergic burden.
The top medications (but by no means limited
to) that are implicated through a review of no fewer
than six articles (Tune et al., 1992; Carnahan et al.,
2006; Boustani et al., 2008;Minton et al., 2009; Fox
et al., 2011; Hori et al., 2011), by class, in descend-
ing order of impact and frequency of prescription
are as follows:
1. Tricyclic antidepressants (e.g. amitriptyline,
doxepin),
2. some “typical” antipsychotics (e.g. trifluoperazine),
3. some SSRIs (e.g. paroxetine),
4. atropine∗
(∗not frequently used clinically, but it is often used
as a benchmark for standardized scores/levels re-
flecting anticholinergic activities).
The cumulative anticholinergic burden con-
sidered clinically significant is 3 or greater. For ex-
ample, amitriptyline on its own would satisfy that
requirement, as will a combination of amantadine
and atenolol, or a triple combination of frusemide,
metoprolol, and digoxin (a very commonly used
combination for congestive heart failure; Krum and
Teerlink, 2011).
What do they do to the frail patient?
One notable feature of anticholinergic “burden”
(unwanted anticholinergic activity is often referred
to as “burden” by the researchers in this area) is
the effect on the CNS (Hori et al., 2011). Hori
et al. (2011) compared two groups of Alzheimer’s
disease patients with possible other co-morbidities
who were hospitalized, and distinguished the two
sample groups as “with serum anticholinergic activ-
ity (SAA) burden” and “without SAA burden.”
When they compared the performance in the Mini-
Mental State Examination (MMSE), for example,
the groups that were free of SAA burden outper-
formed their counterparts by a margin of over 48%
(13.16 vs. 8.89, p = 0.0367). Delirium and beha-
vioral disturbance was also significantly differenti-
ated between the groups, with margins sometimes
as large as three-fold compared with burden-free
subjects. For the purposes of this study, however,
dosage adjustments were not part of the scope, and
therefore no consideration was given to the dosage,
method of delivery, or “doubling-up” of both in any
one patient’s medication regimen. In other words,
any one agent will only attract a single score on the
total ACB (e.g. oxybutynin given in both oral and
transdermal forms will attract the score of 3 once).
Prevention and minimization
From the perspective of clinical pharmacy, the fo-
cal basis of practice appears to be one of prevention
rather than “cure” (Spinewine et al., 2007). Home
Medication Review (HMR), in its current form in
Australia, is based upon two basic elements – op-
timizing the medication regime by aligning med-
ical practitioners’ prescribing habits with best evid-
ence, and improving adherence by patient consulta-
tion and counseling. Both of these elements are
proven to be effective in reducing hospital admis-
sion and overall cost to the public health system
from a general perspective (Desborough et al., 2011;
Maidment et al., 2012). The other reason would
be the quality of life for those patients. It is often
associated with self-empowerment and independ-
ence, and this can only be achieved by preventing
and minimizing the need for hospital admission and
stay. This approach also reduces the possible com-
pounding of the problem, as it is found, the ACB
in a large number of patients actually increased after
discharge from hospital (Wawruch et al., 2012).
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Table 1. Summary of characteristics of patients studied
NUMBER OF
PATIENTS
AGE GROUP
(AGE IN YEARS)
PERCENTAGE OF PATIENTS
IN THIS AGE GROUP
PERCENTAGE OF
MALE VS. FEMALE
.........................................................................................................................................................................................................................................................................................................................
2,236 65–105 95.5% 30.8% vs. 69.2%
This current study takes a theoretical approach,
whereby individual patients are given consideration
for the possibility of a reduction in their overall ACB
bymeans of altering their currentmedication regime
based on relevant practice guidelines.
Method
The scope of this study was to target a group of pa-
tients who can be identified as “elderly,” and pos-
sibly frail. The population studied in this project
consists of residents in sheltered accommodation or
in nursing facilities with varying degrees of support
for activities of daily living, and all receive theirmed-
ications in a DAA. A de-identified database of 2,236
such patients was analyzed. With approval from the
CSU School of Biomedical Sciences Ethics Com-
mittee, these data were drawn from a community
pharmacy’s DAA database, containing the profiles
of medications that these patients were currently
receiving, in a period of approximately four weeks.
The data were extracted without identifiers by staff
at Webstercare
R©
(Leichardt, NSW) and passed to
the research team as an AccessTM database. Table 1
highlights some of the characteristics of the patients
as given by Webstercare
R©
.
Exclusions
There were some patients excluded from this ana-
lysis in order to preserve the quality of the final ana-
lysis and the impact of relevant individual results
are not skewed or “diluted” in any way.
To be included, the patients needed to be using
at least one regular medication with systemic ef-
fects. For this reason, any topical agents with little
to no quantifiable systemic effects were excluded,
such as lubricant eye drops, topical corticosteroids,
and skin wash liquids. Following a similar logic, pa-
tients who are taking oral agents but with little to
no quantifiable systemic effects, were also excluded.
These included the likes of stand-alone daily, low-
dose fiber supplements, simple antacids, and nutri-
tional supplements (e.g. Two Cal
R©
).
Identification
There are a few set criteria as to how and why agents
are identified to be significant for the purposes of
this study.
The Anticholinergic Cognitive Burden (ACB)
scoring is based primarily on the works of two
groups: Boustani et al. (2008) and Sittironnarit et al.
(2011). Boustani et al. (2008) used a list of medic-
ations that are classified into three groups, giving
each a score according to their apparent impact of
anticholinergic effects on cognitive abilities. Scores
are given from 1–3, with a positive correlation to the
highest score with maximum impact. This forms the
basis of identification of most of the agents that are
included in this study. Sittironanarit et al. (2011)
used a different and more recent list of equivalent
medications using similar scales. Although the two
lists are largely overlapping, they do differ in terms
of the medications included and the scores assigned
to them. In order to achieve an adequately compre-
hensive range of medications, both lists are used in
this study.
In order to reduce the possibility of over-
representing the extent of the impact and to achieve
consistency, wherever there is discrepancy between
the two groups in the scoring of individual agents,
Boustani et al. (2008) have been given precedence
and adhered to throughout the study. In order to
be consistent with the logic used while compiling
these lists, some agents are necessarily excluded
from the study. Agents that exhibit no signific-
ant systemic actions will be excluded, even if they
are obviously (and intentionally) anticholinergic in
nature, such as inhaled ipratropium or tiotropium.
There is no definitive evidence that these agents
cross the blood–brain barrier and elicit any signi-
ficant impact on the CNS and therefore cognitive
function. For practical considerations, short-term
medications, such as a course of antibiotics or ben-
zodiazepines, were excluded, since this study fo-
cuses on the long-term therapeutic outcomes. Sim-
ilarly, onlymedications that were “current” in status
were included, any change in dosage and/or com-
mercial brands was counted once, since no consid-
eration of dosage-adjustment was given for the pur-
poses of this study.
Analysis
Given the criteria mentioned above, the number
of patients was then determined to be 691 (n =
691). Each patient’s profile was then analyzed, and
the number and total score of implicated agents
were identified using the ACB by Boustani et al.
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(2008). The theoretical intervention was to at-
tempt to identify the likely indication of each of
these agents, and substitute an alternative for them
wherever possible, as permissible by the current
Australian Therapeutic Guidelines and Australian
Medicines Handbooks as sources of evidence-based
“best practice” standard (Neurology Expert Group,
2010; AMH, 2012). For example, if a patient
was using amitriptyline (ACB = 3) with regular
paracetamol and no antidepressants, then the like-
lihood of it being used as an adjuvant agent for
neuropathic pain is high. However, the possibility
of it being used as a sole antidepressant is also con-
sidered. In this case the results of substitution from
amitriptyline to pregabalin (ACB = 0, for neuro-
pathic pain) and to sertraline (ACB = 0, for de-
pression) are identical, which represent an absolute
reduction in total ACB by 3. Where there was a dis-
crepancy in reduction between the two (or more)
possible indications, the most conservative option
was applied. An example of that would be pro-
methazine (ACB = 3), which could be substituted
with loratadine (ACB = 1, as an antihistamine) for
a reduction of two points; or domperidone (ACB =
0, for nausea) for a reduction of three points, then
the former is preferred unless there is obvious evid-
ence to the contrary (e.g. the patient is concurrently
using a different antihistamine).
Although this study is only based on theoretical
intervention, it takes note of the limitations as to
what changes are possible without impacting the
overall therapeutic effectiveness of each patient’s in-
dividual regime. This is a theoreticalmodel where the
prescribers’ intentions and rationale for the use of
each agent is not always clear. As such, the authors
did not attempt to cease any medication based on
assumptions of “not needed.” Patients who are on
clozapine, for example, would be largely left un-
changed. That is due to the sensitive nature of the
medication both in terms of side effects and drug in-
teractions, and the fact that they are required to be
under the care of a specialist psychiatrist and sub-
jected to regular full blood examinations (FBEs) as
required by practice guidelines in Australia.
The two groups of results – the initial total ACB
and the final ACB after possible reductions – were
then subjected to a “Paired-Samples T-test” using
SPSS
R©
in order to ascertain whether or not the two
groups are “significantly different,” to demonstrate
a meaningful outcome.
Results
Of the 691 patients analyzed in this study, 242 of
them (35%) were found to be using at least one
anticholinergic agent on a regular basis at the time
of the study with significant systemic effects and
thus contributing to the overall ACB. Forty-nine
of these patients (20%) attracted a score of 3 or
above on the ACB, which is deemed to be clinically
significant (Boustani et al., 2008). Figure 1 shows
the constitution of patients by total ACB. Of the
35% who are using at least one agent on the ACB
scale, an absolute reduction is possible in 59% of
them (n = 143).
Further, it appears possible to reduce those from
having an ACB score of 3 or above to a clinically
insignificant score of 2 or less in 85% of the cases
(n = 42). This would mean that the total percent-
age of patients who are potentially affected by a
clinically significant anticholinergic burden could
be reduced from 7.10% to 1.01%. Figure 2 shows
the number of patients classified by resultant ACB
scores after theoretical interventions.
In a Paired-Samples T-test, comparing the res-
ults of the ACB load before and after theoretical in-
tervention, it was found that the correlation between
the two sets of data (before and after the theoretical
intervention) is 0.692 (p< 0.001). The ACB scores,
however, were reduced after the intervention, and
the difference is 0.331. The 95% CI (df = 690)
does not contain the value of 0 (i.e. 0.272–0.391),
and therefore it may be concluded that there is a
significant difference between the two sets of data
and the null hypothesis (H0) is rejected. This can be
confirmed by the fact that significance of the t-value
is <0.001.
This study also found that of the 246,960 counts
of items dispensed and recorded (both prescription
and non-prescription) for this group of patients,
47,334 (or 19.2%) of them were of agents on the
ACB scale.
Discussion
This theoretical study found that 35% of the pa-
tients are taking at least one agent contributing to
ACB, 20% of whom have a clinically significant
score of 3 or above; It suggests that absolute reduc-
tion of ACB is possible in 59% of the patients, and
it is possible to bring 85% of those scored 3 or more
to a score of 2 or less. The exceptions to the possib-
ility of a successful intervention can include, but are
not limited to, the example of clozapine mentioned
in “Methods” section. Due to the well-known po-
tential for clozapine to cause, among other things,
neutropenia or even pancytopenia, rigid monitor-
ing of full blood count (FBC) results is mandat-
ory for any patient enrolled into the Clozapine pro-
gram (Kuluris, 2007; Ronaldson et al., 2011). The
specific course of treatment is tailored by psychi-
atrists who, with expertise in their field, are also
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Figure 1. (Colour online) Number of patients categorized by total (individual) AC Load.
responsible for the overall therapeutic outcome of
the patient. For this, and many other clinical reas-
ons (such as drug interactions, brittle but stabilized
regimens involving warfarin, phenytoin, digoxin,
etc.), the physician in charge of the patient may
not agree with proposed interventions from phar-
macists. Therefore, at this early stage of evidence
gathering, it cannot be conclusively stated that such
interventions are successful or even possible. An-
other aspect of technical difficulties that the re-
searchers encountered is to determine whether or
not to include certain agents at various doses, since
the ACB is not dosage-adjusted in the scope of this
study. One significant example is codeine, which is
recognized by a number of experts in the area to
attract an ACB of at least 1. However, given that
quantitative measures, such as SAA, are restricted
to a laboratory setting and are not practicably avail-
able to a clinical study, it is difficult to ascertain
whether or not lower dosage formulations should
be included (Carnahan et al., 2006). Codeine phos-
phate 30 mg (with or without a combination with
paracetamol) should obviously be considered; how-
ever, products containing doses of 15 mg or less
(typically 8 mg) are less considered. That is partic-
ularly an issue when it is only used on a pro re nata
(PRN) basis, whereby the frequency and dosage
at each dosing time is very difficult to determine
from the available data. The gross inclusion of all
“codeine-based” products will skew the results to
reflect that more patients are afflicted with an ACB
than there are in reality – even if it only attracts a
clinically insignificant score of 1 on its own. In order
to keep in line with the approach for consistency and
inclusiveness, the researcher has decided to include
them as it is listed on the two ACB scoring lists.
Lastly, the theoretical intervention conducted in
this study is limited to “ideal situations.” Many
practical considerations, such as Pharmaceutical
Benefits Scheme (PBS) or private cost of each
medicine, are crucial in the decision-making of
pharmaco-therapeutic regimens. The obvious dif-
ferences, such as amitriptyline ($8.54–8.99) versus
pregabalin ($42.75–183.24) in the treatment of
neuropathic pain, and oxybutynin ($14.48) versus
solifenacin ($56.45–79.30) for urinary incontin-
ence, are indeed as large as these are signific-
ant (MIMS Australia, 2012). Other issues such as
treatment-resistance and non-compliance are taken
into account in this study, but only to the extent
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Figure 2. (Colour online) Patients grouped by ﬁnal AC score for each individual studied after theoretical intervention.
of “minimizing” the impact rather than complete
circumvention (e.g. lowering ACB by substituting
prochloperazine with domperidone instead of sim-
ilarly effective and safe agent such as ondansetron
for nausea – for cost reasons).
For these and many other possible reasons, fur-
ther studies are absolutely necessary to validate, dis-
pute, or otherwise build on these findings. The au-
thors envision this study as a preliminary step to
much larger, actual clinical intervention studies. At
the time of writing, such intervention studies have
commenced in this area. Interventions that could
be suggested to the clinicians and researchers may
include, for example, a protocol in which “every
ACB-contributing agent intended for use is to be
checked against relevant guidelines for a lower-ACB
equivalent before prescribing.”
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